HT-29产品图

HT-29

收藏
  • 询价
  • 2026年09月29日
    avatar
    15 年金牌会员
  • 企业认证

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 细胞形态:

      上皮样

    • 运输方式:

      冻存运输

    • 年限:

      44 years adult

    • 器官来源:

      结肠

    • 相关疾病:

      大肠癌

    • ATCC Number:

      HTB-38™

    • 库存:

      大量

    • 物种来源:

      人

    • 是否是肿瘤细胞:

      1

    • 生长状态:

      贴壁生长

    Designations: HT-29
    Depositors:  J Fogh
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: adherent
    Organism: Homo sapiens
    Morphology: epithelial

    Source: Organ: colon
    Disease: colorectal adenocarcinoma
    Cellular Products: secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth factor beta binding protein; mucin
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
    Isolation: Isolation date: 1964
    Applications: transfection host (Roche Transfection Reagents )
    Receptors: human adrenergic alpha2A [23560 ]
    urokinase receptor (u-PAR)
    vitamin D (moderate expression)
    urokinase receptor (u-PAR); vitamin D (moderate expression)
    Tumorigenic: Yes
    Oncogene: myc +; ras +; myb +; fos +; sis +; p53 +; abl -; ros -; src -
    Antigen Expression: Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 11,12
    D13S317: 11,12
    D16S539: 11,12
    D5S818: 11,12
    D7S820: 10
    THO1: 6,9
    TPOX: 8,9
    vWA: 17,19
    Cytogenetic Analysis: modal number = 71; range = 68 to 72.
    The stemline chromosome number is hypertriploid with the 2S component occurring at 2.4%. Seventeen marker chromosomes are found in most metaphases, generally in single copy per chromosome. The marker designations are: M1p-(=t(3p-;?) with a deleted short arm), t(7q;?), t(10q;?), i(13q), 19q+a; M6, ?t(8q;9q-), ?Xp, M9, 6q+, t(13;?)a, t(13;?)b, 19q+b, M14, M15, 15p+, and Xq-. Chromosome 13 is nullisomic and chromosomes 8 and 14 are generally monosomic. No Y chromosome was detected by QM band analysis.
    Isoenzymes: AK-1, 1
    ES-D, 1
    G6PD, B
    GLO-I, 1-2
    Me-2, 1
    PGM1, 1-2
    PGM3, 1-2
    Age: 44 years adult
    Gender: female
    Ethnicity: Caucasian
    Comments: Ultrastructural features reported for HT-29 cells include microvilli, microfilaments, large vacuolated mitochondria with dark granules, smooth and rough endoplasmic reticulum with free ribosomes, lipid droplets, few primary and many secondary lysosomes. The cells express urokinase receptors, but do not have detectable plasminogen activator activity [PubMed ID: 8381394]. HT-29 cells are negative for CD4, but there is cell surface expression of galactose ceramide (a possible alternative receptor for HIV). The line is positive for expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and fos oncogenes. The p53 antigen is overproduced, and there is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution. N-myc oncogene expression was not detected.
    There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution.
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Temperature: 37.0°C
    Subculturing: Protocol:
    1. Remove and discard culture medium.
    2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
    3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
      Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
    4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
    5. Add appropriate aliquots of the cell suspension to new culture vessels.
    6. Incubate cultures at 37C.

    Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
    Medium Renewal: 2 to 3 times per week
    Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
    Storage temperature: liquid nitrogen vapor temperature
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
    recommended serum:ATCC 30-2020
    derivative:ATCC CCL-218
    purified DNA:ATCC HTB-38D
    References: 18385: Didier ES, et al. Characterization of Encephalitozoon (Septata) intestinailis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43, 1996. PubMed: 8563708
    21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.
    22411: Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642
    22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
    22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
    22564: Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832
    22570: Fantini J, et al. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion. J. Virol. 66: 580-585, 1992. PubMed: 1727501
    22807: Butzow R, et al. A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans. J. Cell Biol. 122: 721-727, 1993. PubMed: 8335695
    22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874
    22866: Hanski C, et al. Tumorigenicity, mucin production and AM-3 epitope expression in clones selected from the HT-29 colon carcinoma cell line. Int. J. Cancer 50: 924-929, 1992. PubMed: 1372882
    22867: Reiter LS, et al. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer 53: 444-450, 1993. PubMed: 8381394
    22996: Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498
    23105: Shabahang M, et al. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53: 3712-3718, 1993. PubMed: 8393379
    23154: Lesuffleur T, et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT- 29 cell subpopulations. J. Cell Sci. 106: 771-778, 1993. PubMed: 8308060
    23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
    23335: Fantini J, et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA 90: 2700-2704, 1993. PubMed: 8464878
    23560: Devedjian JC, et al. Regulation of the alpha 2A-adrenergic receptor in the HT29 cell line. Effects of insulin and growth factors. J. Biol. Chem. 266: 14359-14366, 1991. PubMed: 1677644
    25093: Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479
    32248: Bermudez LE, et al. Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells. Infect. Immun. 65: 3768-3773, 1997. PubMed: 9284150
    32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066
    32282: Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 57: 3672-3677, 1997. PubMed: 9288770
    32297: Morin PJ, et al. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93: 7950-7954, 1996. PubMed: 8755583
    32376: White LJ, et al. Attachment and entry of recombinant norwalk virus capsids to cultured human and animal cell lines. J. Virol. 70: 6589-6597, 1996. PubMed: 8794293
    32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
    32910: Wang R, et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc. Natl. Acad. Sci. USA 93: 8425-8430, 1996. PubMed: 8710887
    32923: Young SW, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 93: 6610-6615, 1996. PubMed: 8692865
    32929: Groh V, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450, 1996. PubMed: 8901601
    33045: Takahashi K, et al. Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem. 271: 9490-9496, 1996. PubMed: 8621620

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标询价记录
    图标暂无询价记录
    图标文献和实验
    相关实验
    • Identification of the Myosin Heavy Polypeptide 9 as a Downstream Effector of the Proprotein Convertases in the Human Colon Carcinoma HT-29 Cells

      colon cancer-specific targets and/or biomarkers. Using the human colon cancer cells HT-29 and ProteinChip arrays analysis that apply the surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), we identified

    • 【求助】5-Fu诱导结肠癌HT-29细胞凋亡的浓度是多少啊

      letong1424 本人想用5-Fu诱导结肠癌HT-29细胞凋亡,查了文献好像大家用的浓度差别很大啊,不知道该怎样选择。如果哪:)位朋友在做相关的研究,请赐教! freecell 引用一篇文章的结果来解决你的问题,该文章被引用237次,方法及结果应该可信。 http://cancerres.aacrjournals.org/cgi/content/abstract/57/12/2452

    • 小鼠5羟色胺(5-HT)酶联免疫分析(ELISA)

      小鼠5羟色胺(5-HT) 酶联免疫 分析(ELISA) 试剂 盒使用说明书 本试剂仅供研究使用          目的:本试剂盒用于测定小鼠血清,血浆及相关液体样本中 5羟色胺(5-HT)的 含量。 实验原理 :     本试剂盒应用双抗体夹心法测定 标本 中 小鼠 5羟色胺 (5-HT) 水平。用纯化的 小鼠 5羟色胺 (5-HT)   抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入 5羟色胺 (5-HT) , 再与HRP 标记

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1320
    博辉生物科技(广州)有限公司
    2025年09月24日询价
    ¥1280
    上海康朗生物科技有限公司
    2026年09月29日询价
    ¥1480
    上海酶研生物科技有限公司
    2026年05月11日询价
    ¥680
    上海联迈生物工程有限公司
    2025年07月28日询价
    ¥800
    上海沪震实业有限公司
    2025年07月08日询价
    HT-29
    询价